National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Clinical Trials (PDQ®)
Patient VersionHealth Professional Version
Last Modified: 9/5/2008     First Published: 7/23/2005  
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Colorectal Cancer Drugs Require Careful Patient Selection

Cetuximab for Advanced Lung Cancer

Past Highlights
Phase III Randomized Study of Adjuvant Zoledronate Versus Clodronate Versus Ibandronate in Women With Resected Primary Stage I-III Adenocarcinoma of the Breast

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Related Information
Registry Information

Alternate Title

Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase III


Treatment


Active


18 and over


NCI


SWOG-S0307
NCCTG-SWOG-S0307, ECOG-SWOG-S0307, NSABP-SWOG-S0307, CALGB-SWOG-S0307, CAN-NCIC-SWOG-S0307, S0307, NCT00127205

Special Category: CTSU trial, NCI Web site featured trial

Objectives

  1. Compare disease-free survival and overall survival of women with resected primary stage I-III adenocarcinoma of the breast treated with adjuvant zoledronate vs clodronate vs ibandronate.
  2. Compare the distributions of sites of first disease recurrence in patients treated with these drugs.
  3. Compare adverse events in patients treated with these drugs.
  4. Correlate parathyroid hormone related protein status and N-telopeptide levels at baseline with disease-free survival and sites of first recurrence in patients treated with these drugs.

Entry Criteria

Disease Characteristics:

  • Histologically confirmed primary adenocarcinoma of the breast
    • Stage I-III disease
    • No evidence of metastatic disease


  • Must have undergone lumpectomy or total mastectomy for primary disease within the past 12 weeks, or have completed chemotherapy within the past 8 weeks
    • Axillary evaluation per institutional standards


  • Currently receiving or planning to receive standard adjuvant systemic therapy comprising chemotherapy, hormonal therapy, or combined chemotherapy/hormonal therapy for breast cancer
    • Patients who are at low risk for disease recurrence and for whom adjuvant systemic therapy will not be prescribed are not eligible
    • Patients who receive biologic agents only or local radiotherapy only (without chemotherapy and/or hormone therapy) are not eligible
    • Additional therapies are allowed including radiotherapy and biologic agents (e.g., trastuzumab [Herceptin®], bevacizumab, or hematopoietic growth factors)
    • Neoadjuvant therapy is allowed provided study entry occurs after completion of surgery


  • Patients with skeletal pain are eligible provided bone scan and/or roentgenological exam are negative for metastatic disease
    • Suspicious findings must be confirmed as benign by x-ray, MRI, or biopsy


  • Hormone receptor status:
    • Not specified


Prior/Concurrent Therapy:

Biologic therapy

  • Prior or concurrent hematopoietic growth factors allowed
  • HER-2-targeted therapies allowed
  • Antiangiogenics allowed

Chemotherapy

  • See Disease Characteristics

Endocrine therapy

  • See Disease Characteristics

Radiotherapy

  • Concurrent radiotherapy to the breast, chest wall, or lymph node group allowed at the discretion of the treating physician

Surgery

  • See Disease Characteristics

Other

  • Prior neoadjuvant therapy allowed
  • Prior bisphosphonates for bone density allowed
  • No other concurrent bisphosphonates as adjuvant therapy or for treatment of osteoporosis
  • No concurrent enrollment in clinical trials with bone density as an endpoint (i.e., CAN-NCIC-MA27)
    • Concurrent enrollment on any other locoregional or systemic therapy breast cancer study (including cooperative group studies) allowed

Patient Characteristics:

Age

  • 18 and over

Sex

  • Female

Menopausal status

  • Not specified

Performance status

  • Zubrod 0-2

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Creatinine ≤ 2 times upper limit of normal
  • Creatinine clearance ≥ 30 mL/min
  • No renal failure

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No history of esophageal stricture or motility disorders
    • Gastroesophageal reflux disorder allowed
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission

Expected Enrollment

4500

A total of 4,500 will be accrued for this study.

Outcomes

Primary Outcome(s)

Histologic confirmation of disease recurrence
Sites of first disease recurrence
Disease-free survival
Overall survival
Zubrod performance status

Outline

This is a randomized, multicenter study. Patients are randomized to 1 of 3 treatment arms.

  • Arm I: Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.


  • Arm II: Patients receive oral clodronate once daily for 3 years.


  • Arm III: Patients receive oral ibandronate once daily for 3 years.


Treatment in all arms continues in the absence of disease recurrence or unacceptable toxicity.

After completion of study treatment, patients are followed every 6 months until disease recurrence and then annually for up to 10 years.

Trial Contact Information

Trial Lead Organizations

Southwest Oncology Group

Julie Gralow, MD, Study coordinator
Ph: 206-288-7722
Email: pink@u.washington.edu
Robert Livingston, MD, Study coordinator
Ph: 206-288-1085

North Central Cancer Treatment Group

James Ingle, MD, Study coordinator
Ph: 507-284-2511
Email: ingle.james@mayo.edu

Eastern Cooperative Oncology Group

Carla Falkson, MD, Study coordinator
Ph: 205-975-2691
Email: cfalkson@uab.edu

National Surgical Adjuvant Breast and Bowel Project

Alexander Paterson, MD, FRCP, FACP, MBChB, Study coordinator
Ph: 403-521-3688
Email: alexpate@cancerboard.ab.ca

Cancer and Leukemia Group B

Elizabeth Dees, MD, Study coordinator
Ph: 919-843-7714

NCIC-Clinical Trials Group

Mark Clemons, MD, Study coordinator
Ph: 416-480-5847
Email: mark.clemons@sw.ca

Trial Sites

U.S.A.
Alabama
  Anniston
 Regional Medical Center
 Stephanie Fussell
Ph: 256-235-5877
  Birmingham
 Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
 Clinical Trials Office - Lurleen Wallace Comprehensive Cancer
Ph: 205-934-0309
  Mobile
 Providence Cancer Center at Providence Hospital
 Paul Schwarzenberger, MD
Ph: 251-435-5892
Alaska
  Anchorage
 Alaska Regional Hospital Cancer Center
 Saul Rivkin, MD
Ph: 206-386-2929
 Providence Cancer Center
 Clinical Trials Office - Providence Cancer Center
Ph: 907-261-3109
  Fairbanks
 Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
 Jacqueline Vuky
Ph: 907-458-5380
800-678-5458
Arizona
  Tucson
 Arizona Cancer Center at University of Arizona Health Sciences Center
 Clinical Trials Office - Arizona Cancer Center at University of Arizona Health Sciences Center
Ph: 520-626-9008
Arkansas
  Bentonville
 Highlands Oncology Group - Springdale
 Joseph Beck, MD, FACP
Ph: 479-751-2100
  Hot Springs
 St. Joseph's Mercy Cancer Center
 Prabhakara Reddy
Ph: 501-623-2731
  Little Rock
 Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
 Clinical Trial Office - Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Ph: 501-686-8274
California
  Arroyo Grande
 Arroyo Grande Community Hospital
 David Palchak, MD
Ph: 805-473-8983
  Burbank
 Providence Saint Joseph Medical Center - Burbank
 Clinical Trials Office - Providence Saint Joseph Medical Center - Burbank
Ph: 818-847-3220
  Castro Valley
 East Bay Radiation Oncology Center
 James Feusner, MD
Ph: 510-428-3689
 Eden Medical Center
 James Feusner, MD
Ph: 510-428-3689
 Valley Medical Oncology Consultants - Castro Valley
 James Feusner, MD
Ph: 510-428-3689
  Fairfield
 North Bay Cancer Center
 Clinical Trials Office - North Bay Cancer Center
Ph: 707-429-6976
  Fremont
 Kaiser Permanente - Fremont
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 Valley Medical Oncology
 James Feusner, MD
Ph: 510-428-3689
  Glendale
 Glendale Memorial Hospital Comprehensive Cancer Center
 Clinical Trials Office - Glendale Memorial Hospital Comprehensive Cancer Center
Ph: 818-409-7653
  Grass Valley
 Sierra Nevada Cancer Center at Sierra Nevada Memorial Hospital
 Clinical Trials Research Nurse
Ph: 530-274-6635
  Hayward
 Kaiser Permanente Medical Center - Hayward
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  La Jolla
 Rebecca and John Moores UCSD Cancer Center
 Clinical Trials Office - Rebecca and John Moores UCSD Cancer Center
Ph: 858-822-5354
 Email: cancercto@ucsd.edu
  Long Beach
 Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center
 Clinical Trials Office - Breastlink Medical Group, Incorporated
Ph: 562-981-6101
  Los Angeles
 USC/Norris Comprehensive Cancer Center and Hospital
 Clinical Trials Office - USC/Norris Comprehensive Cancer Center and Hospital
Ph: 323-865-0451
  Marysville
 Tibotec Therapeutics - Division of Ortho Biotech Products, LP
 Helen Chew, MD
Ph: 916-734-3771
  Modesto
 Memorial Medical Center
 Clinical Trials Office - Memorial Medical Center
Ph: 209-572-7116
  Oakland
 Alta Bates Summit Medical Center - Summit Campus
 Clinical Trials Office - Alta Bates Summit Medical Center - Summit Campus
Ph: 510-204-1414
 Bay Area Breast Surgeons, Incorporated
 James Feusner, MD
Ph: 510-428-3689
 CCOP - Bay Area Tumor Institute
 James Feusner, MD
Ph: 510-428-3689
 Highland General Hospital
 James Feusner, MD
Ph: 510-428-3689
 Kaiser Permanente Medical Center - Oakland
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 Larry G Strieff MD Medical Corporation
 James Feusner, MD
Ph: 510-428-3689
 Tom K Lee, Incorporated
 James Feusner, MD
Ph: 510-428-3689
  Pleasanton
 Valley Care Medical Center
 James Feusner, MD
Ph: 510-428-3689
 Valley Medical Oncology Consultants - Pleasanton
 James Feusner, MD
Ph: 510-428-3689
  Pomona
 Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
 Clinical Trials Office - Robert and Beverly Lewis Family Cancer Care Center
Ph: 909-865-9555
  Redding
 Mercy Regional Cancer Center at Mercy Medical Center
 Clinical Trials Office - Mercy Regional Cancer Center
Ph: 530-225-7471
  Redwood City
 Kaiser Permanente Medical Center - Redwood City
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Richmond
 Kaiser Permanente Medical Center - Richmond
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Roseville
 Kaiser Permanente Medical Center - Roseville
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Sacramento
 Kaiser Permanente Medical Center - Sacramento
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 South Sacramento Kaiser-Permanente Medical Center
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 University of California Davis Cancer Center
 Clinical Trials Office - University of California Davis Cancer Center
Ph: 916-734-3089
  San Francisco
 Kaiser Permanente Medical Center - San Francisco Geary Campus
 Louis Fehrenbacher, MD
Ph: 707-651-2577
 San Francisco General Hospital Medical Center
 Judith Luce, MD
Ph: 415-206-8000
 UCSF Helen Diller Family Comprehensive Cancer Center
 Clinical Trials Office - UCSF Helen Diller Family Comprehensive Cancer Center
Ph: 877-827-3222
  San Jose
 Kaiser Permanente Medical Center - Santa Teresa
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  San Pablo
 Doctors Medical Center - San Pablo Campus
 James Feusner, MD
Ph: 510-428-3689
  San Rafael
 Kaiser Foundation Hospital - San Rafael
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Sana Rosa
 CCOP - Santa Rosa Memorial Hospital
 Ian Anderson, MD
Ph: 707-521-3830
  Santa Clara
 Kaiser Permanente Medical Center - Santa Clara Kiely Campus
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Santa Rosa
 Kaiser Permanente Medical Center - Santa Rosa
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  South San Francisco
 Kaiser Permanente Medical Center - South San Francisco
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Stockton
 Kaiser Permanente Medical Facility - Stockton
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Truckee
 Tahoe Forest Cancer Center
 Helen Chew, MD
Ph: 916-734-3771
  Vallejo
 Kaiser Permanente Medical Center - Vallejo
 Louis Fehrenbacher, MD
Ph: 707-651-2577
  Walnut Creek
 Kaiser Permanente Medical Center - Walnut Creek
 Louis Fehrenbacher, MD
Ph: 707-651-2577
Colorado
  Aurora
 University of Colorado Cancer Center at UC Health Sciences Center
 Clinical Trials Office - University of Colorado Cancer Center
Ph: 720-848-0650
  Colorado Springs
 Memorial Hospital Cancer Center - Colorado Springs
 Clinical Trials Office - Memorial Hospital
Ph: 719-365-2406
  Denver
 Denver Health Medical Center
 Anthony Elias, MD
Ph: 303-436-6000
 Veterans Affairs Medical Center - Denver
 Anthony Elias, MD
Ph: 303-399-8020
888-336-8262
  Edwards
 Shaw Regional Cancer Center
 Anthony Elias, MD
Ph: 970-569-7429
  Glenwood Springs
 Valley View Hospital Cancer Center
 Anthony Elias, MD
Ph: 970-945-6535
  Montrose
 Montrose Memorial Hospital Cancer Center
 Clinical Trials Office - Montrose Memorial Hospital Cancer Center
Ph: 670-240-7267
Connecticut
  Greenwich
 Bendheim Cancer Center at Greenwich Hospital
 Clinical Trials Office - Bendheim Cancer Center
Ph: 203-863-3698
  Hartford
 Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
 Zia Rahman, MD
Ph: 860-714-4680
  Norwalk
 Norwalk Hospital
 Richard Frank, MD
Ph: 203-855-3517
Delaware
  Dover
 Kent General Hospital
 Iftekhar Khan, MD
Ph: 302-674-4700
  Lewes
 Tunnell Cancer Center at Beebe Medical Center
 Clinical Trials Office - Tunnell Cancer Center
Ph: 302-645-3171
  Newark
 CCOP - Christiana Care Health Services
 Clinical Trial Office - CCOP - Christiana Care Health Services
Ph: 302-733-6227
District of Columbia
  Washington
 Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
 Clinical Trials Office - Lombardi Comprehensive Cancer Center
Ph: 202-444-0381
 Washington Cancer Institute at Washington Hospital Center
 Clinical Trials Office - Washington Cancer Institute
Ph: 202-877-8839
Florida
  Boca Raton
 Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - West
 Charles Vogel, MD
Ph: 561-883-7530
 Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus
 Clinical Trials Office - Eugene M. and Christine E. Lynn Cancer Institute
Ph: 561-955-4800
  Fort Lauderdale
 Broward General Medical Center Cancer Center
 Clinical Trials Office - Broward General Medical Center Cancer Center
Ph: 954-355-5346
  Hollywood
 Memorial Cancer Institute at Memorial Regional Hospital
 Clinical Trials Office - Memorial Cancer Institute
Ph: 954-985-3443
  Jacksonville
 Mayo Clinic - Jacksonville
 Clinical Trials Office - All Mayo Clinic Locations
Ph: 507-538-7623
  Lakeland
 Center for Cancer Care and Research at Watson Clinic, LLP
 Clinical Trials Office - Center for Cancer Care and Research
Ph: 863-680-7780
  Stuart
 Robert and Carol Weissman Cancer Center at Martin Memorial
 Alpana Desai
Ph: 772-223-5952
 Alpana Desai